First patent granted to Norwood Immunology

By Melissa Trudinger
Tuesday, 17 February, 2004

Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.

The patent, granted in South Africa, is the first of more than 100 patent applications filed in major jurisdictions around the world covering various aspects of the immunology project.

Director of marketing Bernie Romanin said that the granted patent provided recognition of the breadth of the application of the GnRH technology.

Norwood Immunology is in the process of listing on the London Stock Exchange's AIM market. Romanin said the listing process was progressing according to plan and the company expected it to list mid-year.

Related News

Accurate age estimation with DNA methylation

Using cutting-edge artificial intelligence, scientists created a tool that can determine a...

Algae unlocks a more ethical way to grow cells

Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...

Oral drug shows promise for treating Barth syndrome

An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd